Inavolisib
Inavolisib works by blocking the activity of a protein called PI3K-alpha that signals cells to multiply. It also helps break down mutant (overactive) versions of this protein found in cancer cells. This may keep cancer cells from growing and may kill them. Inavolisib is a type of targeted therapy drug called an enzyme inhibitor. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Inavolisib is approved to be used with palbociclib and fulvestrant to treat adults with:
- breast cancer that is hormone receptor positive and HER2 negative and has an abnormal PIK3CA gene. It is used for cancer that has spread and has come back during or after completing adjuvant hormone therapy.
Inavolisib is also being studied in the treatment of other types of cancer.
More About Inavolisib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Inavolisib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Inavolisib - Check for trials from NCI's list of cancer clinical trials now accepting patients.